Kelli Grinder, MD
Internal Medicine · Fultondale, ALNPI 1528011079
Payments from drug & device makers
Across 585 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$727
- Boehringer Ingelheim$648
- AstraZeneca$628
- GSK$600
- Pfizer$532
- plus $4K from 33 others
What the payments were for
- Food & beverage$8,932100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 145 | $1,899 |
| Lilly USA, LLC | 47 | $727 |
| Boehringer Ingelheim | 49 | $648 |
| AstraZeneca | 33 | $628 |
| GSK | 42 | $600 |
| Pfizer | 36 | $532 |
| Amgen(2 entities) | 27 | $482 |
| AbbVie(2 entities) | 26 | $435 |
| Johnson & Johnson | 19 | $313 |
| Amarin Pharma, Inc. | 19 | $269 |
| Sanofi-aventis U.S. LLC | 12 | $238 |
| E.r. Squibb & Sons, L.L.C. | 14 | $226 |
| Astellas Pharma US Inc | 13 | $224 |
| Merck | 12 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $165 |
| Bayer | 8 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $134 |
| Ironwood Pharmaceuticals, Inc | 9 | $130 |
| Abbott | 6 | $115 |
| Novartis | 6 | $112 |
| Phathom Pharmaceuticals, Inc. | 5 | $100 |
| Sumitomo Pharma America, Inc. | 4 | $92 |
| Supernus Pharmaceuticals, Inc. | 6 | $91 |
| Boston Scientific | 4 | $87 |
| Dexcom, Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Shire North American Group Inc | 2 | $38 |
| Medtronic | 2 | $34 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Eisai Inc. | 2 | $27 |
| Genentech USA, Inc. | 1 | $22 |
| Corium, LLC | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
How this compares
$8,958 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 362 | $480,771 |
| MounjaroTirzepatide | 199 | $281,897 |
| EliquisApixaban | 210 | $236,081 |
| JardianceEmpagliflozin | 154 | $162,883 |
| RybelsusSemaglutide | 64 | $116,371 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $93,456 |
| GlyxambiEmpagliflozin/Linagliptin | 88 | $84,517 |
| TradjentaLinagliptin | 74 | $73,808 |
| Tresiba Flextouch U-100Insulin Degludec | 109 | $68,687 |
| TrulicityDulaglutide | 50 | $66,938 |
| LinzessLinaclotide | 53 | $59,439 |
| Breo ElliptaFluticasone/Vilanterol | 80 | $50,753 |
| MyrbetriqMirabegron | 53 | $42,350 |
| Tresiba Flextouch U-200Insulin Degludec | 60 | $41,166 |
| XareltoRivaroxaban | 32 | $39,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,899 | $597,142426 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Combivent Respimat, Spiriva Respimat | $648 | $350,873343 claims |
| Lilly USA, LLCMounjaro, Trulicity | $727 | $348,835249 claims |
| PfizerEliquis, Premarin | $532 | $244,202229 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $600 | $152,100184 claims |
| AbbVieLinzess | $435 | $59,43953 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $42,35053 claims |
| Johnson & JohnsonXarelto | $313 | $39,74232 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $134 | $35,29911 claims |
| NovartisEntresto | $112 | $31,92838 claims |
| MerckJanuvia, Janumet | $186 | $28,54532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Fultondale
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.